brimonidine has been researched along with xylazine in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (50.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Batink, H; de Jonge, A; Thoolen, MJ; Timmermans, PB; van Zwieten, PA; Wilffert, B | 1 |
de Jonge, A; Lam, E; Slothorst-Grisdijk, FP; Timmermans, PB; van Meel, JC; van Zwieten, PA | 1 |
Bonhaus, DW; Chang, LK; Chang, TK; Daunt, DA; Eglen, RM; Hsu, SA; Jasper, JR; Lesnick, JD; Yamanishi, SS | 1 |
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
4 other study(ies) available for brimonidine and xylazine
Article | Year |
---|---|
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Blood Pressure; Brain; Cell Membrane; Clonidine; Kinetics; Prazosin; Quinazolines; Rats; Receptors, Adrenergic, alpha; Structure-Activity Relationship; Vasoconstriction | 1984 |
Characterization of alpha-adrenoceptor populations. Quantitative relationships between cardiovascular effects initiated at central and peripheral alpha-adrenoceptors.
Topics: Animals; Blood Pressure; Blood Vessels; Brain; Hemodynamics; Male; Rats; Receptors, Adrenergic; Receptors, Adrenergic, alpha | 1981 |
Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding.
Topics: Adenylyl Cyclases; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Cell Line; Cell Membrane; Cyclic AMP; Genetic Vectors; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Ligands; Mice; Protein Binding; Quinolizines; Radioligand Assay; Receptors, Adrenergic, alpha-2; Recombinant Proteins | 1998 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |